Harvard Medical School: COVID-19 Vaccine Trial Launches
July 28, 2020
July 28, 2020
BOSTON, Massachusetts, July 28 -- Harvard Medical School issued the following news:
A candidate vaccine for preventing COVID-19 is advancing to a 30,000-participant phase 3 trial starting July 27, and Brigham and Women's Hospital will play two key roles in the trial.
The phase 3 COVE study will evaluate mRNA-1273, a vaccine candidate against COVID-19 manufactured by Moderna. The study will enroll participants at locations throughout the United States, with Brigham and W . . .
A candidate vaccine for preventing COVID-19 is advancing to a 30,000-participant phase 3 trial starting July 27, and Brigham and Women's Hospital will play two key roles in the trial.
The phase 3 COVE study will evaluate mRNA-1273, a vaccine candidate against COVID-19 manufactured by Moderna. The study will enroll participants at locations throughout the United States, with Brigham and W . . .